๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Linyi
Clinical trial register · China

Clinical Trials in Linyi, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Gan & Lee Pharmaceuticals.5 Qilu Hospital of Shandong University4 Capital Medical University3 Hoffmann-La Roche2 Bristol-Myers Squibb2
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Linyi

48 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Bioequivalence Study of GZR4 Injection With Different Manufacturing Processes in Healthy Adult Participants
NCT07670897T2D
Gan & Lee Pharmaceuticals.
Phase 1
64
Linyi
2026-07-01
Recruiting
A Study of TAK-755 in Adults With Acute Ischemic Stroke
NCT07392450Acute Ischemic Stroke
Takeda
Phase 2
222
Beijing, Nanyang, Xuzhou, Jinan, Liaocheng, Linyi, Datong, Linfen
2026-05-17
Recruiting
Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke
NCT07509645Ischemic Stroke
Capital Medical University
Phase 3
348
Suzhou, Anyang, Nanyang, Xinxiang, Zhoukou, Linyi, Zibo, Xianyang
2026-04-22
Recruiting
Phase โ…ข Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
NCT07390123IgA Nephropathy (IgAN)
Haisco Pharmaceutical Group Co., Ltd.
Phase 3
370
Huangshan City, Wuhu, Beijing, Zhanjiang, Changsha, Changchun, Linyi, Shanghai
2026-04-07
Not yet open
Intracalvariosseous Plus Intravenous Antibiotics for Moderate-to-Severe Bacterial Meningitis
NCT07495150Blood-Brain Barrier, Bacterial Meningitis
yilong Wang
Not applicable
86
Beijing, Kaifeng, Xinxiang, Zhengzhou, Linyi, Tianjin
2026-04-01
Recruiting
Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment
NCT07498478Breast Cancer
TransThera Sciences (Nanjing), Inc.
Phase 2
94
Guangzhou, Wuhan, Changsha, Nanjing, Jinan, Linyi, Hangzhou, Beijing
2026-03-17
Recruiting
A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Phase โ…ข Clinical Trial Evaluating the Efficacy and Safety of BXOS110 Injection in the Treatment of Acute Ischaemic Stroke Within 3 Hours of Onset.
NCT07520565AIS
Biocells (Beijing) Biotech Co.,Ltd
Phase 3
1,112
Hengshui, Daqing, Nanyang, Meihekou, Shenyang, Xianyang, Linyi, Linfen
2026-01-19
Recruiting
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
NCT07276581Rheumatoid Arthritis
AstraZeneca
Phase 2
320
Beijing, Changchun, Changsha, Guangzhou, Jiujiang, Kunming, Linyi, Nanchong
2025-12-15
Active, closed
HRS-7450 Injection Phase II Clinical Trial for Acute Ischemic Stroke.
NCT07233070Acute Ischemic Stroke
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 2
210
Guangzhou, Linyi
2025-10-31
Recruiting
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
NCT07205822Breast Cancer
AstraZeneca
Phase 3
100
Beijing, Changsha, Guangzhou, Linyi, Shandong, Wuhan, Zhengzhou
2025-10-30
Recruiting
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
NCT07173751Breast Neoplasms
BioNTech SE
Phase 3
558
Changde, Hefei, Jinan, Lanzhou, Linyi, Nanchang, Nanjing, Neijiang
2025-10-30
Active, closed
Pharmacokinetic and Safety Study of GZR4 Injection in Subjects With Hepatic Impairment
NCT07193147Diabetes
Gan & Lee Pharmaceuticals.
Phase 1
36
Linyi
2025-10-20
Recruiting
A Phase IIIb Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin
NCT07165223Diabetes
Gan & Lee Pharmaceuticals.
Phase 3
300
Linyi
2025-10-17
Recruiting
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
NCT07022483Endometrial Cancer
Daiichi Sankyo
Phase 3
710
Beijing, Changchun, Chengdu, Hangzhou, Jinan, Linyi, Nanchang, Nanning
2025-09-30
Recruiting
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
NCT06855771Carcinoma, Non-Small-Cell Lung
Bristol-Myers Squibb
Phase 2
182
Beijing, Xiamen, Nanning, Nanchang, Jinan, Linyi, Hangzhou, Linhai
2025-09-09
Recruiting
DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
NCT07059650Diffuse Large B-Cell Lymphoma
Dizal Pharmaceuticals
Phase 1/2
150
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Taiyuan
2025-08-19
Active, closed
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer
NCT06799286Small Cell Lung Carcinoma
Bristol-Myers Squibb
Phase 1
10
Beijing, Jinan, Linyi, Hangzhou, Shanghai
2025-05-07
Recruiting
Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma
NCT06932068HER2 Negative, Low PD-L1 Expressing, Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Qilu Hospital of Shandong University
Phase 2
77
Zhengzhou, Binzhou, Dezhou, Dongying, Jinan, Jining, Liaocheng, Linyi
2025-03-26
Active, closed
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naรฏve Participants With Active Psoriatic Arthritis
NCT06878404Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 3
552
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Linyi
2025-02-21
Active, closed
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM)
NCT06767735Diabetes
Gan & Lee Pharmaceuticals.
Phase 3
580
Linyi
2025-02-17
Active, closed
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin
NCT06767748Diabetes
Gan & Lee Pharmaceuticals.
Phase 3
620
Linyi
2025-02-15
By invitation
A Phase III Clinical Study of Valsartan Oral Solution for the Treatment of Hypertension in Children and Adolescents
NCT06863987Essential Hypertension
Shandong New Time Pharmaceutical Co., LTD
Phase 3
342
Linyi
2025-02-05
Recruiting
Minimally Invasive Soft Channel Brain Haemorrhage Evacuation for Acute Basal Ganglia Haemorrhage-- Large Hemorrhage Evacuation (MIRACLE-L)
NCT06688201Intracerebral Hemorrhage
Capital Medical University
Not applicable
550
Linyi
2025-01-04
Recruiting
A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors
NCT06725381Solid Malignancies
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
138
Guangzhou, Nanning, Wuhan, Changsha, Nanjing, Jinan, Linyi, Chengdu
2024-12-17
Recruiting
Study on Hibernation-like Therapy Based on Mechanical Thrombectomy
NCT06663631Acute Ischemic Stroke
Capital Medical University
Phase 1
32
Linyi
2024-11-09
Recruiting
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
NCT06730373HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma
Qilu Hospital of Shandong University
Phase 2
110
Zhengzhou, Binzhou, Dongying, Jinan, Jining, Liaocheng, Linyi, Qingdao
2024-10-17
Recruiting
A Research Protocol for Evaluating the Efficacy of Perfused Chemotherapeutic Agents for Bladder Cancer Based on Organoid Technology
NCT06662071Bladder Cancer
Qilu Hospital of Shandong University
Observational
293
Binzhou, Dezhou, Jinan, Jining, Liaocheng, Linyi, Qingdao, Taian
2024-10-01
By invitation
A Phase โ…ก/โ…ข Study of Rulonilimab Plus Chemotherapyยฑ Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
NCT06755515Cervical Cancer
Shandong New Time Pharmaceutical Co., LTD
Phase 2/3
510
Linyi
2024-09-26
Recruiting
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972Systemic Lupus Erythematosus
Novartis Pharmaceuticals
Phase 3
550
Guangzhou, Shantou, Nanjing, Suzhou, Nanchang, Pingxiang, Changchun, Linyi
2024-05-21
Recruiting
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
NCT06385925Malignant Neoplasm
Tyligand Pharmaceuticals (Suzhou) Limited
Phase 1/2
440
Hefei, Beijing, Guangzhou, Wuhan, Changsha, Nanchang, Linyi, Shanghai
2024-04-29
Active, closed
Evaluation of the Ton-bridge Carotid Stent for Carotid Artery Stenosis
NCT06365697Carotid Artery Stenosis
Ton-Bridge Medical Tech. Co., Ltd
Not applicable
188
Shenyang, Linyi, Qingdao, Jinan, Lishui, Beijing
2024-04-24
Recruiting
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
NCT06385080Squamous Cell Carcinoma of Head and Neck
Janssen Research & Development, LLC
Phase 1/2
287
Beijing, Cheng Du Shi, Linyi, Shanghai, Wuhan
2024-04-22
Recruiting
pBFS Guided rTMS Over Cognitive Control Network for ASD
NCT06255535Autism Spectrum Disorder
Changping Laboratory
Not applicable
215
Fuzhou, Baoding, Xi'an, Jining, Linyi
2024-04-01
Recruiting
A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor
NCT06758557Advanced NSCLC, Advanced Endometrial Cancer
Huabo Biopharm Co., Ltd.
Phase 1/2
282
Baoding, Harbin, Luoyang, Zhengzhou, Lianyungang, Shenyang, Jinan, Linyi
2024-01-31
Recruiting
A Multi-center RCT to Evaluate Subsegmental BTVA Treatment for Severe Emphysema
NCT06152107Severe Emphysema
Shanghai Chest Hospital
Not applicable
100
Zhengzhou, Beijing, Chengdu, Linyi, Nanchang, Shanghai, Shijiazhuang, Zhejiang
2024-01-01
Recruiting
SY001 Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors
NCT06562647Treatment Related Cancer, Ovarian Cancer
Cell Origin Biotech (Hangzhou) Co., Ltd.
Not applicable
2
Hangzhou, Linyi
2023-04-12
Active, closed
Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy
NCT05585580Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Qilu Hospital of Shandong University
Phase 2
59
Jinan, Qingdao, Yantai, Linyi
2023-03-01
Recruiting
A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
NCT05615974Malignant Tumors
LaNova Medicines Limited
Phase 1/2
139
Guangzhou, Wuhan, Linyi, Beijing, Shanghai
2023-01-11
Recruiting
Effective Translation of Endovascular Thrombectomy Trials Into Real-world Practice in the Asia-Pacific
NCT05578300Ischemic Stroke, Stroke, Stroke, Acute, Stroke, Ischemic
Chinese University of Hong Kong
Observational
350
Linyi, Qingdao
2022-10-21
Active, closed
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
NCT05537740Advanced Solid Tumors
Bayer
Phase 1
129
Guangzhou, Changchun, Linyi
2022-10-11
Active, closed
A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naรฏve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
NCT05047250Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 3
60
Beijing, Changsha, Chongqing, Fuzhou, Hangzhou, Hefei, Linyi, Nanjing
2022-06-14
Recruiting
A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors
NCT05217693Solid Tumor
Bliss Biopharmaceutical (Hangzhou) Co., Ltd
Phase 1
288
Beijing, Changsha, Ganzhou, Hangzhou, Hanzhou, Linyi, Nanjing
2022-06-01
Active, closed
Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
NCT05280470Extensive-stage Small-cell Lung Cancer
Daiichi Sankyo
Phase 2
187
Changchun, Changsha, Chengdu, Guangdong, Hangzhou, Linyi, Shanghai, Wuhan
2022-03-09
Recruiting
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
NCT04892173Carcinoma, Squamous Cell
Johnson & Johnson Enterprise Innovation Inc.
Phase 3
500
Bengbu, Changsha, Chengdu, Dongguan, Fuzhou, Guangzhou, Jinan, Linyi
2021-12-10
Recruiting
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
NCT04913285Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
Pierre Fabre Medicament
Phase 1
400
Haerbin, Linyi, Beijing, Shanghai
2021-08-04
Recruiting
A Clinical Study to Evaluate Efficacy and Safety of Serplulimab๏ผˆHLX10๏ผ‰ Combined With Bevacizumab๏ผˆHLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)
NCT04547166Metastatic Colorectal Cancer
Shanghai Henlius Biotech
Phase 2/3
568
Guangzhou, Hangzhou, Linyi, Shanghai
2021-03-10
Active, closed
A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
NCT04632108Malignant Solid Tumor
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase 1/2
199
Beijing, Linyi
2021-01-28
Active, closed
A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
NCT04576455Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche
Phase 2
303
Changchun, Guangzhou, Linyi, Nanchang, Shanghai, Tianjin, Wuhan, Xi'an
2020-11-27
Rows per page Showing 1–48 of 48
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/linyi

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 48 of those studies with a site in Linyi.

How many clinical trials are recruiting in Linyi?

31 of the 48 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 13 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Linyi), 48 studies
PhaseStudiesRecruitingShare
Phase 314929.2%
Phase 210620.8%
Phase 18416.7%
Not applicable6412.5%
Phase 1/26512.5%
Observational224.2%
Phase 2/3214.2%

Most active sponsors

Lead sponsors with the most studies (Linyi)
Lead sponsorStudiesRecruiting
Gan & Lee Pharmaceuticals.51
Qilu Hospital of Shandong University43
Capital Medical University33
AstraZeneca22
Bristol-Myers Squibb21
Daiichi Sankyo21
Hoffmann-La Roche20
Janssen Research & Development, LLC21
Shandong New Time Pharmaceutical Co., LTD20
Bayer10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.